Literature DB >> 28892311

[How i treat a patient with idiopathic pulmonary fibrosis].

J Guiot1, B Duysinx1, O Bonhomme2, R Louis2, J-L Corhay2.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a rare disorder of unknown origin, which is associated with a high mortality and whose incidence has been increasing for several years. Nowadays there are two anti-fibrotic therapies (pirfenidone - nintedanib) known to reduce significantly the decline in respiratory function tests of patients suffering from this condition. The only curative therapeutic option remains the pulmonary transplantation whose accessibility remains limited. Pulmonary rehabilitation is also central in the treatment of patients. A major challenge for patients remains early and aggressive management to reduce as early as possible the evolution towards severe pulmonary fibrosis.

Entities:  

Keywords:  Interstitial lung disease; Nintedanib ; Pirfenidone ; Idiopathic pulmonary fibrosis

Mesh:

Year:  2017        PMID: 28892311

Source DB:  PubMed          Journal:  Rev Med Liege        ISSN: 0370-629X


  1 in total

1.  Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.

Authors:  Julien Guiot; Makon-Sébastien Njock; Béatrice André; Fanny Gester; Monique Henket; Dominique de Seny; Catherine Moermans; Michel G Malaise; Renaud Louis
Journal:  Sci Rep       Date:  2021-05-25       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.